BAX:NYE-Baxter International Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 36.57

Change

0.00 (0.00)%

Market Cap

USD 18.71B

Volume

4.55M

Analyst Target

USD 96.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-09 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

N/A

USD 65.91B
ALC Alcon AG

N/A

USD 46.01B
RMD ResMed Inc

N/A

USD 34.14B
AVTR Avantor Inc

N/A

USD 11.92B
ATR AptarGroup Inc

N/A

USD 10.16B
TFX Teleflex Incorporated

N/A

USD 7.78B
STVN Stevanato Group SpA

N/A

USD 5.98B
BLCO Bausch + Lomb Corp

N/A

USD 5.64B
WRBY Warby Parker Inc

N/A

USD 3.17B
INFU InfuSystems Holdings Inc

N/A

USD 0.17B

ETFs Containing BAX

EUSA iShares MSCI USA Equal We.. 0.21 % 0.15 %

N/A

USD 1.21B
PBI Pitney Bowes Inc 0.00 % 0.79 %

N/A

USD 1.74B
QDIV Global X S&P 500® Qualit.. 0.00 % 0.00 %

N/A

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.41% 100% F 98% N/A
Dividend Return 0.58% 100% F 34% F
Total Return 25.99% 100% F 98% N/A
Trailing 12 Months  
Capital Gain -16.45% 42% F 15% F
Dividend Return 2.10% 80% B- 36% F
Total Return -14.35% 42% F 15% F
Trailing 5 Years  
Capital Gain -55.93% 19% F 7% C-
Dividend Return 6.44% 57% F 15% F
Total Return -49.49% 31% F 7% C-
Average Annual (5 Year Horizon)  
Capital Gain -18.88% 5% F 3% F
Dividend Return -17.15% 5% F 3% F
Total Return 1.73% 80% B- 41% F
Risk Return Profile  
Volatility (Standard Deviation) 17.60% 84% B 60% D-
Risk Adjusted Return -97.42% 5% F 1% F
Market Capitalization 18.71B 79% B- 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector